Biotech Values

[DewDiligence]

>> Patients reaching a certain age, symptoms, past personnel history or family history would probably all use these tests. <<

True. When you move to a high-risk subgroup, rather than the general population, the mathematics become much more favorable as the specificity (avoidance of false positives) improves dramatically.

However, restricting a test to high-risk patients can kill the economic rationale for the business. I wish you the best with your MZT but I continue to think that cancer diagnostics are a tough way to make money.